Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330–343 (2023).
Voena, C., Ambrogio, C., Iannelli, F. & Chiarle, R. ALK in cancer: from function to therapeutic targeting. Nat. Rev. Cancer 25, 359–378 (2025).
Shaw, A. T. et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann. Oncol. https://doi.org/10.1016/j.annonc.2026.05.692 (2026).
Saifudeen, M. et al. Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03090-8 (2026).
Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714–729 (2018).
Igawa, Y. et al. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. Lung Cancer 196, 107954 (2024).
Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101–114 (2017).
Gao, Y. et al. Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. J. Med. Chem. 66, 5524–5535 (2023).
Kang, C. H. et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Biochem. Biophys. Res. Commun. 505, 542–547 (2018).
Li, X. et al. A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. iScience 27, 109015 (2024).
Ren, C. et al. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from alectinib. Eur. J. Med. Chem. 217, 113335 (2021).
Sun, N. et al. Development of a brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur. J. Med. Chem. 193, 112190 (2020).
Yan, G. et al. Discovery of a PROTAC targeting ALK with in vivo activity. Eur. J. Med. Chem. 212, 113150 (2021).
Zhang, C. et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur. J. Med. Chem. 151, 304–314 (2018).
La, D. S., Nasveschuk, C. G. & Gilbert, A. M. in 2025 Medicinal Chemistry Reviews Medicinal Chemistry Reviews (eds Rudolph, J. & Watkins, W.) 399–427 (ACS, 2025).
Kozicka, Z. & Thoma, N. H. Haven’t got a glue: protein surface variation for the design of molecular glue degraders. Cell Chem. Biol 28, 1032–1047 (2021).
Vetma, V., O’Connor, S. & Ciulli, A. Development of PROTAC degrader drugs for cancer. Annual Rev. Cancer Biol. 9, 119–140 (2025).
Agarwal, P., Reid, D. L. & Amiji, M. CNS delivery of targeted protein degraders. J. Control. Release 372, 661–673 (2024).
Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem. Neurosci. 7, 767–775 (2016).
La, D. et al. Anaplastic lymphoma kinase (ALK) degraders and uses thereof. US patent WO/2026/035999 (2026).
Drilon, A. et al. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat. Rev. Clin. Oncol. 18, 35–55 (2021).
Camidge, D. R. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J. Thorac. Oncol. 16, 528–531 (2021).
Liu, D. et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann. Oncol. 31, 1207–1215 (2020).
Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252–257 (2016).
Nishiguchi, G. et al. Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nat. Commun. 15, 482 (2024).
Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679–690 (2011).
Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549–553 (2022).
Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127–130 (2016).
Petzold, G. et al. Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition. Science 389, eadt6736 (2025).
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
Shiba-Ishii, A. et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat. Cancer 3, 710–722 (2022).
Highlights of Prescribing Information for Lorbrena https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf (2021).
Zou, H. Y. et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28, 70–81 (2015).
Taipale, M. et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630–637 (2013).
Pacheco, J. M. et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J. Thorac. Oncol. 14, 691–700 (2019).
Lin, J. J. et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 14, 2367–2386 (2024).
Poirson, J. et al. Proteome-scale discovery of protein degradation and stabilization effectors. Nature 628, 878–886 (2024).
Reichermeier, K. M. et al. PIKES analysis reveals response to degraders and key regulatory mechanisms of the CRL4 network. Mol. Cell 77, 1092–1106 e1099 (2020).
Orthofer, M. et al. Identification of ALK in thinness. Cell 181, 1246–1262 (2020).
Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981–987 (2018).
Lin, J. J. et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J. Clin. Oncol. 44, 8503–8503 (2026).
Dagogo-Jack, I. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26, 2535–2545 (2020).
Eide, C. A. et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell 42, 1486–1488 (2024).
Nagasaka, M. et al. The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib. NPJ Precis. Oncol. https://doi.org/10.1038/s41698-026-01477-z (2026).
Bird, S. & Pawlyn, C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 142, 131–140 (2023).
Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393–401 (2023).
Katayama, R. et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20, 5686–5696 (2014).
de la Rosa-Trevin, J. M. et al. Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 195, 93–99 (2016).
Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).
Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519–530 (2018).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr. D 77, 1282–1291 (2021).
Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243–250 (2015).
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics https://doi.org/10.1093/bioinformatics/btq054 (2010).
Yamazaki, S. et al. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J. Pharmacol. Exp. Ther. 351, 67–76 (2014).
%20SOURCE%20Julian%20Chokkattu(2).jpg "The Fairphone (Gen 6+) Review: Finally in the US")
